NORWOOD, Mass.--(BUSINESS WIRE)--Aspect Medical Systems, Inc. (NASDAQ: ASPM) today announced that study results from the BRITE (Biomarkers for Rapid Identification of Treatment Effectiveness) trial in major depression demonstrate that the company’s EEG-based Antidepressant Treatment Response (ATR) indicator is a significant predictor of patient response and remission from depression when utilized one week following initiation of treatment with escitalopram.
